DDrare: Database of Drug Development for Rare Diseases

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-flumazenil; 18F-FTC-146; ACIDUM ASCORBICUM D6; AF056; AFQ056; AZD7325; AZD7325 (High-Dose); AZD7325 (Low-Dose); Acamprosate; Acetate; Acidum ascorbicum; Alpha-tocopherol; Ampalex; Arbaclofen; Aripiprazole; Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E); Ascorbic acid; BPN14770; CBD; CCD 1042, MD 9150000, Mepalon 1042, SPT316; CX516; CX516 (Ampalex®); Donepezil; EGCG; EGCG FontUp; Flumazenil; Fluoxetin; GANAXOLONE; Gaboxadol; Ganaxolone; Lovastatin; Lovastatin, then Minocycline/Lovastatin; MG01CI extended-release tablet; MGlu5 antagonist; Mavoglurant; Metformin; Methylphenidate; Methylphenidate, fluoxetin, risperidone; Minocycline; Minocycline hydrochloride; Minocycline, then Minocycline/Lovastatin; NNZ-2566; NPL-2009; OV101; OV101 (gaboxadol); Other: Biological samples; Other: Cognitive training; Other: Language Intervention; Other: MRI; Oxytocin; Oxytocin 24IU; Oxytocin 48IU; RO4917523; RO4917523 0.5 mg; RO4917523 1.5 mg; Riluzole; Risperidone; Ro 491-7523/F18; Ro 491-7523/F19; STX107; STX209; Sertraline; Sugar pill; TOCOPHERYL ACETATE; Tocopherol; Tocopheryl acetate; Vitamin C; Vitamin C 10mg/Kg Vitamin E 10 mg/Kg; Vitamin E; ZYN002 - CBD Transdermal Gel; [18F]FPEB; [18F]FPEB PET imaging; [18F]flumazenil

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02719951 (ClinicalTrials.gov)	April 2016	9/3/2016	Glutaminergic Transmission in Autism : Molecular Imaging Exploration	Glutaminergic Transmission in Autism : Molecular Imaging Exploration	Autism;Fragile-X Syndrome (FXS);Healthy Volunteers	Drug: [18F]FPEB PET imaging;Other: Biological samples;Other: MRI	University Hospital, Tours	NULL	Completed	18 Years	45 Years	Male	27	Phase 1	France
2	NCT00870974 (ClinicalTrials.gov)	March 2009	26/3/2009	A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions	Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions	Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment	Drug: [18F]FPEB	Institute for Neurodegenerative Disorders	NULL	Completed	18 Years	85 Years	All	48	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02719951
(ClinicalTrials.gov)

April 2016

9/3/2016

Glutaminergic Transmission in Autism : Molecular Imaging Exploration

Autism;Fragile-X Syndrome (FXS);Healthy Volunteers

Drug: [18F]FPEB PET imaging;Other: Biological samples;Other: MRI

University Hospital, Tours

NULL

Completed

18 Years

45 Years

Male

Phase 1

France

NCT00870974
(ClinicalTrials.gov)

March 2009

26/3/2009

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions

Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment

Drug: [18F]FPEB

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

85 Years

All

Phase 1

United States